Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 390

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment

Open access
Kiess, Ana P., Wolchok, Jedd D., Barker, Christopher A., Postow, Michael A., Tabar, Viviane, Huse, Jason T., Chan, Timothy A., Yamada, Yoshiya, Beal, Kathryn·2015·International Journal of Radiation Oncology*Biology*Physics

Abstract

Purpose Ipilimumab (Ipi), a monoclonal antibody against cytotoxic T-lymphocyte antigen-4, has been shown to improve survival in patients with metastatic melanoma. In this single-institution study, we investigate the safety and efficacy of stereotactic radiosurgery (SRS) for patients with melanoma brain metastases (BMs) who also received Ipi. Methods From 2005 to 2011, 46 patients with melanoma received Ipi and underwent single fraction SRS for BMs. A total of 113 BMs (91% intact, 9% post-operative) were treated with median dose 21Gy (15-24Gy). Ipi was given at 3mg/kg (54%) or 10mg/kg (46%) for a median of 4 doses (1-21). Adverse events were recorded using CTCAE 3.0. Kaplan-Meier methods were used to estimate survival and Cox regression was used to investigate associations. Results Fifteen patients received SRS during Ipi, 19 received SRS before Ipi, and 12 received SRS after Ipi. Overall survival (OS) was significantly associated with timing of SRS/Ipi (p=0.035) and melanoma-specific graded prognostic assessment (p=0.013). Patients treated with SRS during or before Ipi had better OS and less regional recurrence (RR) than those treated with SRS after Ipi (1-yr OS 65% vs. 56% vs. 40%, p=0.008; 1-yr RR 69% vs. 64% vs. 92%, p=0.003). SRS during Ipi also yielded a trend toward less local recurrence (LR) than SRS before or after Ipi (1-yr LR 0% vs. 13% vs. 11%, p=0.21). On MRI, an increase in BM diameter to >150% was seen in 50% of patients treated during or before Ipi but only 13% of patients treated after Ipi. Grade 3-4 toxicities were seen in 20% of patients. Conclusion Overall, the combination of Ipi and SRS appears to be well tolerated. Concurrent delivery of Ipi and SRS is associated with favorable locoregional control and possibly longer survival. It may also cause a temporary increase in tumor size, possibly due to enhanced immunomodulatory effect.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ijrobp.2015.01.004

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 390

Metadata

Authors
Kiess, A. P., Wolchok, J. D., Barker, C. A., Postow, M. A., Tabar, V., Huse, J. T., Chan, T. A., Yamada, Y., & Beal, K.
Venue
International Journal of Radiation Oncology*Biology*Physics
Publisher
Elsevier BV
Published
2015-06
Volume
92
Issue
2
Pages
368-375
ISSN
0360-3016 (ISSN-L)
OpenAlex
W2074933858
Cited by
390
References
27
FWCI
40.91
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment. https://app.cochat.ai/papers/10.1016/j.ijrobp.2015.01.004
The paper
Kiess, A. P., Wolchok, J. D., Barker, C. A., Postow, M. A., Tabar, V., Huse, J. T., Chan, T. A., Yamada, Y., & Beal, K. (2015). Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2015.01.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.